16.08.2013 17:24:00

Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.

LONDON, August 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

The U.S. equity market ended on a lower note on Thursday, August 15, 2013. The Dow Jones Industrial Average closed at 15,112.19, down 1.47%, the S&P 500 closed at 1,661.32, down 1.43%, and the NASDAQ composite finished at 3,606.12, down 1.72%. Shares in the healthcare sector companies also fell, tracking losses in the broader market. The major movers in the sector included Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Orexigen Therapeutics Inc. (NASDAQ: OREX), MAKO Surgical Corporation (NASDAQ: MAKO), and Alere Inc. (NYSE: ALR). AAAResearchReports.com free coverage on VRTX, OREX, MAKO, and ALR is available upon registration at:

http://www.aaaresearchreports.com/register/  

Shares in Vertex Pharmaceuticals Inc. fell sharply on Thursday, tracking losses in the broader market. The company's shares ended the day 1.65% lower at $76.96 after vacillating between $76.60 and $78.26. A total of 1.44 million shares were traded which is below the daily average volume of 1.62 million. Vertex Pharmaceuticals Inc.'s shares have lost 0.67% in the last three trading sessions, compared to a decline of 1.67% in the S&P 500. Despite the recent losses, the company's shares are trading above their 200-day moving average. Download free technical research on VRTX by signing up at:

http://www.AAAResearchReports.com/VRTX081613.pdf

On Thursday, shares in Orexigen Therapeutics Inc. plunged 4.02%. The company's shares traded between $6.90 and $7.19 before ending the day at $6.93. A total of 1.04 million shares were traded which is below the daily average volume of 1.26 million. Orexigen Therapeutics Inc.'s shares have tumbled 4.81% in the last three trading sessions. Despite the recent losses, the company's shares have gained 9.31% in the last one month, and 12.14% in the last three months, outperforming the S&P 500. Register now and get access to free analysis on OREX at:

http://www.AAAResearchReports.com/OREX081613.pdf

Shares in MAKO Surgical Corporation declined on Thursday, extending their recent losses. The company's shares closed the day at $14.15, down 3.08%, after oscillating between $14.10 and $14.49. A total of 0.58 million shares were traded which is below the daily average volume of 0.90 million. The stock has gained 28.52% in the last three months, outperforming the S&P 500 which has gained 0.15% during the same period. Furthermore, the stock is trading above its 50-day and 200-day moving averages. Sign up and read our complimentary report on MAKO at:

http://www.AAAResearchReports.com/MAKO081613.pdf

Alere Inc.'s shares finished the day 2.93% lower on Thursday after rising sharply in the previous trading session. The company's shares vacillated between $31.40 and $32.48 before closing the day at $31.75. A total of 0.63 million shares were traded which is marginally above the daily average volume of 0.61 million. Alere Inc.'s shares have lost 0.84% in the last three trading sessions, outperforming the S&P 500 which has lost 1.67% during the same period. Despite the recent losses, the company's shares have surged 16.69% in the last one month and 19.63% in the last three months, outperforming the S&P 500. The free report on ALR can be downloaded by signing up now at:

http://www.AAAResearchReports.com/ALR081613.pdf

----

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  • For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

  • COMPLIANCE PROCEDURE

    Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

    NOT FINANCIAL ADVICE

    Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

    NO WARRANTY OR LIABILITY ASSUMED

    Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


    AAAresearchreports.com

    SOURCE AAA Research Reports

    Nachrichten zu Alere Incmehr Nachrichten

    Keine Nachrichten verfügbar.

    Analysen zu Alere Incmehr Analysen

    Eintrag hinzufügen
    Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
    Es ist ein Fehler aufgetreten!

    Aktien in diesem Artikel

    Vertex Pharmaceuticals Inc. 442,10 -0,12% Vertex Pharmaceuticals Inc.